Literature DB >> 17100402

Role of apheresis in rheumatoid arthritis.

Sanford H Roth1.   

Abstract

Apheresis, a therapeutic procedure that has been available for decades, has recently been added to the long-term management of rheumatoid arthritis (RA). It is a procedure whereby blood is removed from the body and divided into its various components. With the development of specific instrumentation, it has become possible to target the specific cellular or humoral components to be removed or altered. RA is a destructive, chronic progressive disease with high morbidity and significant mortality if it is not treated. Recently, combinations of disease-modifying pharmacotherapeutic agents have successfully been brought to bear on this serious disease. This approach of combining potent anti-inflammatory, disease-modifying antirheumatic drugs (DMARDs), chemotherapy and biologicals continues with some success but not without significant dangers of severe adverse toxicity, including the risks of sepsis, immunopathology and malignancy. In the setting of RA, various apheresis procedures, with and without these combination modalities, have been tested with variable success. This article reviews that experience as an overall approach to better, safer RA disease management.

Entities:  

Mesh:

Year:  2006        PMID: 17100402     DOI: 10.2165/00003495-200666150-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  28 in total

Review 1.  The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis.

Authors:  J R Caldwell; D E Furst
Journal:  Semin Arthritis Rheum       Date:  1991-08       Impact factor: 5.532

Review 2.  Aspirin, salicylates, and nonsteroidal anti-inflammatory drugs: new class labeling and medical practice.

Authors:  S H Roth
Journal:  Compr Ther       Date:  1991-06

3.  A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis.

Authors:  J Caldwell; R M Gendreau; D Furst; C Wiesenhutter; F Quagliata; J Spindler; J Bertram
Journal:  J Rheumatol       Date:  1999-08       Impact factor: 4.666

4.  Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.

Authors:  T Hidaka; K Suzuki; M Kawakami; M Okada; K Kataharada; T Shinohara; M Takamizawa-Matsumoto; F Ohsuzu
Journal:  J Clin Apher       Date:  2001       Impact factor: 2.821

5.  Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.

Authors:  R Sanmartí; S Marsal; J Valverde; E Casado; R Lafuente; N Kashiwagi; J-R Rodriguez-Cros; A Erra; D Reina; J Gratacós
Journal:  Rheumatology (Oxford)       Date:  2005-05-31       Impact factor: 7.580

6.  A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis.

Authors:  D Wallace; D Goldfinger; C Lowe; S Nichols; J Weiner; M Brachman; J R Klinenberg
Journal:  N Engl J Med       Date:  1982-06-10       Impact factor: 91.245

7.  Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.

Authors:  T Hidaka; K Suzuki; Y Matsuki; M Takamizawa-Matsumoto; M Okada; T Ishizuka; M Kawakami; F Ohsuzu
Journal:  Ther Apher       Date:  1999-05

8.  Risk factors for septic arthritis in patients with joint disease. A prospective study.

Authors:  C J Kaandorp; D Van Schaardenburg; P Krijnen; J D Habbema; M A van de Laar
Journal:  Arthritis Rheum       Date:  1995-12

9.  Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.

Authors:  G Hahn; B Stuhlmüller; N Hain; J R Kalden; K Pfizenmaier; G R Burmester
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

10.  The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.

Authors:  D T Felson; J J Anderson; R F Meenan
Journal:  Arthritis Rheum       Date:  1990-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.